RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study
RC48-ADC 单药治疗或联合免疫疗法治疗 HER2 低表达或无表达的局部晚期或转移性尿路上皮癌:一项多中心、真实世界、回顾性研究
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14154-4
Wang, Daining; Cao, Manming; Zhang, Yijun; Bi, Liangkuan; Chen, Meiting; Ni, Mengqian; Zheng, Qiufan; Yao, Kai; Liu, Zhuowei; Yang, Xia; Shi, Yanxia; Wu, Zhiming; An, Xin